Benzinga | Mar 12, 2021 08:56AM EST

Wolfe Research Initiates Coverage On Horizon Therapeutics with Outperform Rating, Announces Price Target of $107

Wolfe Research analyst Akash Tewari initiates coverage on Horizon Therapeutics (NASDAQ:HZNP) with a Outperform rating and announces Price Target of $107.